Evidence map›Paper›PMID 40662450›Full record

ArticleNeurodegenerative disease management2025

Outcomes of older patients with multiple sclerosis treated with interferon beta-1a or peginterferon beta-1a in MS PATHS.

Le H Hua, Carrie M Hersh, Lana Zhovtis Ryerson, Nick Belviso, Megan Vignos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurodegenerative disease management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Le H HuaDepartment of Neurology, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.ORCID 0000-0002-0535-3978
Carrie M HershDepartment of Neurology, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.ORCID 0000-0002-5716-5645
Lana Zhovtis RyersonDepartment of Neurology, NYU Grossman School of Medicine, New York, NY, USA.
Nick BelvisoBiogen, Cambridge, MA, USA.
Megan VignosBiogen, Cambridge, MA, USA.ORCID 0000-0002-7755-2781

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe peak prevalence of multiple sclerosis (MS) is shifting to older patients. Using real-world data, we describe outcomes among older (≥60 years) and younger patients treated with interferon beta-1a or no disease-modifying therapy (no-DMT).

methodsAssessments over 24 months included annualized relapse rates (ARRs), patient-reported disability outcomes, and MS Performance Test (MSPT) outcomes.

resultsThe study included 767 interferon-treated and 2783 no-DMT patients. ARR over 24 months was lower for the older and younger interferon-treated patients than the no-DMT patients. Mean change in Patient-Determined Disease Steps (PDDS) from baseline-24 months was -0.13 (1.08) in older interferon-treated patients vs 0.20 (1.30) in older no-DMT patients.

conclusionOver 24 months ARR remained low and disability progression was stable for interferon-treated patients aged ≥ 60 years.

Indexed as

Immunologic FactorsInterferon-betaInterferon beta-1aMultiple SclerosisPolyethylene GlycolsAdultAgedAge FactorsDisease ProgressionFemaleHumansMaleMiddle AgedTreatment OutcomeImmunologic FactorsInterferon-betaInterferon beta-1apeginterferon beta-1aPolyethylene GlycolsIntramuscular interferon beta-1aMS PATHSolder patientspeginterferon beta-1areal-world evidence

Identifiers

PMID40662450
PMCPMC12456204

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.